Description
Anti-Interleukin 8 Antibody, Non-Fucosylated (BioBet-758ZP) is a human monoclonal IgG2 antibody against Interleukin 8. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Chronic Bronchitis; Chronic obstructive pulmonary disease; Inflammatory Diseases; Melanoma; Psoriasis; Rheumatoid Arthritis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Interleukin 8 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CXCL8
Full Name
chemokine (C-X-C motif) ligand 8
Background
The protein encoded by this gene is a member of the CXC chemokine family. This chemokine is one of the major mediators of the inflammatory response. This chemokine is secreted by several cell types. It functions as a chemoattractant, and is also a potent angiogenic factor. This gene is believed to play a role in the pathogenesis of bronchiolitis, a common respiratory tract disease caused by viral infection. This gene and other ten members of the CXC chemokine gene family form a chemokine gene cluster in a region mapped to chromosome 4q.
Alternative Names
CXCL8; chemokine (C-X-C motif) ligand 8; IL8; NAF; GCP1; LECT; LUCT; NAP1; GCP-1; LYNAP; MDNCF; MONAP; NAP-1; interleukin-8; emoctakin; interleukin 8; T-cell chemotactic factor; neutrophil-activating peptide 1; beta-thromboglobulin-like protein; granulocyte chemotactic protein 1; tumor necrosis factor-induced gene 1; alveolar macrophage chemotactic factor I; monocyte-derived neutrophil chemotactic factor; monocyte-derived neutrophil-activating peptide; small inducible cytokine subfamily B, member 8; lymphocyte derived neutrophil activating peptide; lung giant cell carcinoma-derived chemotactic protein; beta endothelial cell-derived neutrophil activating peptide
Gene ID
3576
UniProt ID
Q8WTT0
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with CXCL8 include Melanoma and Adult Respiratory Distress Syndrome.
Related Pathways
Its related pathways are Regulation of Wnt-mediated beta catenin signaling and target gene transcription and Transcriptional misregulation in cancer.
Function
IL-8 is a chemokine that can attract neutrophils, basophils and T cells, but not monocytes. It is also involved in the activation of neutrophils. It is released from several types of cells under inflammatory stimuli. Compared with IL-8(1-77), IL-8(6-77) has a 5-10 times higher neutrophil activation activity, and IL-8(5-77) has an increased neutrophil activation activity. The activity is increased, and IL-8 (7-77) has a higher affinity for receptors CXCR1 and CXCR2.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Immune System antibody
Post-translational modifications
Several N-terminal processed forms are produced by proteolytic cleavage after secretion from at least peripheral blood monocytes, leukcocytes and endothelial cells. In general, IL-8(1-77) is referred to as interleukin-8. IL-8(6-77) is the most promiment form. Citrullination at Arg-27 prevents proteolysis, and dampens tissue inflammation, it also enhances leukocytosis, possibly through impaired chemokine clearance from the blood circulation.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG2
Antibody Clone
BioBet-758ZP
Description
This is a human IgG2 monoclonal antibody directed against human IL-8, which should be considered as a treatment modality for other solid tumors in which IL-8 plays an angiogenic role, including bladder, prostate, ovarian and lung cancers. ABX-IL8 was shown to be safe and well tolerated in both the single-dose and the multiple dose trials. No serious or unexpected adverse events have been reported, no immunogenicity has been detected, and there has been no evidence of cytokine release syndrome in either of the trials.
Antibody Indication
Chronic Bronchitis; Chronic obstructive pulmonary disease; Inflammatory Diseases; Melanoma; Psoriasis; Rheumatoid Arthritis
Chronic Bronchitis; Chronic obstructive pulmonary disease; Inflammatory Diseases; Melanoma; Psoriasis; Rheumatoid Arthritis
